Be the first person to write a business review for OXIS International, Inc.

Palatin Technologies, Inc. company was founded in 1986 and is based in Cranbury, New Jersey. Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of peptide, peptide mimetic, and small molecule agonist compounds with a focus on melanocortin (MC) and natriuretic peptide receptor systems in the United States. The company's products under development include PL-3994, a peptide mimetic natriuretic peptide receptor A agonist for the treatment of heart failure; Bremelanotide, a peptide melanocortin receptor agonist for the treatment of sexual dysfunction, targeting female sexual dysfunction and erectile dysfunction in patients non-responsive to current therapies; and PL-6983, a peptide melanocortin receptor agonist for the treatment of female sexual dysfunction. Its products in development also comprise melanocortin receptor-based compounds for treatment of obesity, diabetes, and related metabolic syndrome; and NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection. Palatin Technologies, Inc. has a licensing and research collaboration agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome.

Photopharmica Ltd. discovers and develops photo sensitizers and light sources for medical use in the United Kingdom. The company develops anti-infective agents primarily for dermatology and wound management markets; and medical devices in the fields of orthopedics and periodontal equipment. Its products pipeline includes phenothiazinium photo sensitizers for use as topical therapeutic antimicrobial agents; phenothiazinium photo sensitizers for systemic oncology use; and phthalocyanine photo sensitizers that combine anti-tumor properties with minimal or zero skin photo sensitization. Photopharmica Ltd. was founded in 2001 and is based in Leeds, the United Kingdom.

Precision Therapeutics, Inc. company was founded in 1995 and is headquartered in Pittsburgh, Pennsylvania. Precision Therapeutics, Inc., a diagnostics services company, engages in the development and delivery of treatment support tools for physicians and cancer patients in the United States and Canada. The company develops predictive drug response tests, which include ChemoFx, a drug response marker test that quantifies a cancer patient's probable tumor response to various chemotherapeutic and biologic agents and provides sensitivity and resistance information, such as tumor progression, increased side effects, accumulated toxicity, development of cross-resistance, decreased efficacy of future treatments, and decreased quality of life. It offers physicians and patients with clinical information to personalize cancer treatments.

Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts. Pressure BioSciences, Inc. (PBI) focuses on the development and commercialization of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. The company holds 13 U.S. and 6 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical (primarily enzymatic) reactions, immunodiagnostics, and protein purification. PBI focuses on the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications. It serves academic laboratories; government agencies; and biotechnology, pharmaceutical, and life science companies. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2004 as a result of change in business strategy.

Quality Assured Services (QAS) is a direct marketer of point-of-care and self-testing diagnostic products. It distributes easy-to-use diagnostic kits directly to consumers' homes, as well as to health professionals and home health care providers. Its products include anticoagulation tests, cholesterol tests, and other products that monitor and diagnose such conditions as blood pressure, diabetes, lung function, and infectious diseases. The company also provides telemedicine support, patient management software, insurance verification, and billing services. QAS is a subsidiary of diagnostic products firm Inverness Medical Innovations.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.